- Home
- EMF vs CMPX Comparison
EMF vs CMPX Comparison
Compare EMF & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMF
- CMPX
- Stock Information
- Founded
- EMF 1987
- CMPX 2014
- Country
- EMF United States
- CMPX United States
- Employees
- EMF N/A
- CMPX N/A
- Industry
- EMF Finance/Investors Services
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- EMF Finance
- CMPX Health Care
- Exchange
- EMF Nasdaq
- CMPX Nasdaq
- Market Cap
- EMF 192.8M
- CMPX 214.6M
- IPO Year
- EMF N/A
- CMPX N/A
- Fundamental
- Price
- EMF $12.19
- CMPX $2.61
- Analyst Decision
- EMF
- CMPX Strong Buy
- Analyst Count
- EMF 0
- CMPX 4
- Target Price
- EMF N/A
- CMPX $13.75
- AVG Volume (30 Days)
- EMF 29.3K
- CMPX 2.2M
- Earning Date
- EMF 01-01-0001
- CMPX 11-12-2024
- Dividend Yield
- EMF 6.16%
- CMPX N/A
- EPS Growth
- EMF N/A
- CMPX N/A
- EPS
- EMF N/A
- CMPX N/A
- Revenue
- EMF N/A
- CMPX $850,000.00
- Revenue This Year
- EMF N/A
- CMPX N/A
- Revenue Next Year
- EMF N/A
- CMPX $613.39
- P/E Ratio
- EMF N/A
- CMPX N/A
- Revenue Growth
- EMF N/A
- CMPX N/A
- 52 Week Low
- EMF $10.58
- CMPX $0.77
- 52 Week High
- EMF $12.67
- CMPX $2.73
- Technical
- Relative Strength Index (RSI)
- EMF 51.56
- CMPX 77.12
- Support Level
- EMF $11.71
- CMPX $2.34
- Resistance Level
- EMF $12.29
- CMPX $2.70
- Average True Range (ATR)
- EMF 0.13
- CMPX 0.29
- MACD
- EMF 0.05
- CMPX 0.12
- Stochastic Oscillator
- EMF 82.76
- CMPX 90.98
About EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company. It seeks long-term capital appreciation by investing, under normal market conditions, at least 80% of its net assets in emerging country equity securities. It invests in various sectors such as Pharmaceuticals, Beverages, Broadline Retail, Metals &Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, insurance, Entertainment, and others.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.